FINWIRES · TerminalLIVE
FINWIRES

Entropy Neurodynamics Executes Agreement for Manufacturing of Proprietary Therapy Candidate; Shares Up 3%

By

Entropy Neurodynamics (ASX:ENP) executed a development and manufacturing services agreement with BioCina to manufacture its proprietary therapy candidate, TRP-8803, or IV-infused psilocin, according to a Wednesday Australian bourse filing.

BioCina will conduct a program including analytical verification, engineering batch manufacture, followed by GMP placebo and active drug product batches, per the filing. The manufacturing program is expected to take 24 weeks, with real-time stability studies continuing for 24 months.

Entropy is advancing TRP-8803 through a clinical program, including a 72-patient study across eight neuropsychiatric indications of high-unmet clinical need, the filing said. The agreement provides the manufacturing capability to support clinical trials and future regulatory requirements.

The company's shares climbed nearly 3% in recent trading on Wednesday.

Related Articles

Asia

Wasco Greenergy Appoints Group MD as CEO Opts for Early Retirement

Wasco Greenergy (KLSE:GENERGY) said its chief executive officer, Lee Yee Chong, opted for early retirement from the role, effective Dec. 31, according to a Monday filing with Bursa Malaysia.Shares slid over 2% in Tuesday's late morning trade.Lee joined the group in 1995 and has held several key leadership positions within Wasco over the years.The company appointed Wong Yin Kee as group managing director, effective Aug. 17, to facilitate the transition of authority and responsibilities.

KLSE:GENERGY
Asia

Yuntianhua's H1 Profit Rises 6%, Revenue Drops 9%; Shares Up 3%

Yunnan Yuntianhua's (SHA:600096) net profit attributable to shareholders for the first half rose 6.1% to 2.93 billion yuan from 2.76 billion yuan a year earlier, according to a Tuesday disclosure on the Shanghai bourse.Earnings per share increased year on year to 1.61 yuan from 1.52 yuan.Operating revenue fell 8.9% to 22.8 billion yuan from 25.1 billion yuan in the previous year.The board of directors proposed a cash dividend of 2 yuan for every 10 shares.The high-quality diammonium phosphate supplier's shares rose nearly 3% during the morning trade.

SHA:600096
Asia

Market Chatter: CJ Group Sets KRW12 Trillion Revenue Target for North America by 2028

CJ Group expects its total revenue from North America to expand to 12 trillion won by 2028, driven by rising demand for Korean food, entertainment, and beauty products, The Korean Times reported Monday.The South Korean group, led by holding company CJ (KRX:001040), unveiled its target following a strategy meeting with the group chairman in Los Angeles last week.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

KRX:001040